CoChat
Sign Up
Cited by 80

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation

Kuwahara, Tomoki, Funakawa, Kai, Komori, Tadayuki, Sakurai, Maria, Yoshii, Gen, Eguchi, Tomoya, Fukuda, Mitsunori, Iwatsubo, Takeshi·2020·Neurobiology of Disease
DOI 10.1016/j.nbd.2020.105081

Published version of a preprint

Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2020.105081

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Rab10 was identified as phosphorylated by LRRK2 combining two independent genetic and chemical phosphoproteomic screens and has been validated in subsequent studies.

    “Rab10 specifically was identified as phosphorylated by LRRK2 combining two independent genetic and chemical phosphoproteomic screens and has been validated in subsequent studies [19, 28, 32, 34, 35, 41, 79].”

    From Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain (2023) · cites this paper as [32]

    The Introduction identifies Rab10 as an LRRK2 substrate, and the Discussion reports this paper’s own findings on LRRK2-mediated Rab10 phosphorylation. The copy does not say Rab10 was identified by combining two independent genetic and chemical phosphoproteomic screens; it cites Steger et al. (2016) for the earlier identification. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 67

  1. Aizawa, 2015, Small GTPase Rab2B and its specific binding protein Golgi-associated Rab2B interactor-like 4 (GARI-L4) regulate Golgi morphology, J. Biol. Chem., 290, 22250, 10.1074/jbc.M115.669242 · DOI
  2. Anderson, 1999, Comparison of preservative-free bupivacaine vs. lidocaine for intracameral anesthesia: a randomized clinical trial and in vitro analysis, Am J. Ophthalmol., 127, 393, 10.1016/S0002-9394(98)00417-6 · DOI
  3. Atilla, 2003, Effects of intracameral lidocaine on ocular tissues, Clin. Exp. Ophthalmol., 31, 73, 10.1046/j.1442-9071.2003.00604.x · DOI
  4. Baba, 1998, Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies, Am. J. Pathol., 152, 879
  5. Baptista, 2013, Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs, PLoS One, 8, 10.1371/journal.pone.0080705 · DOI
  6. Barrett, 2008, Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease, Nat. Genet., 40, 955, 10.1038/ng.175 · DOI · Paper page
  7. Bawolak, 2010, Vacuolar ATPase-mediated sequestration of local anesthetics in swollen macroautophagosomes, Can. J. Anaesth., 57, 230, 10.1007/s12630-009-9220-9 · DOI
  8. Beilina, 2014, Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease, Proc. Natl. Acad. Sci. U. S. A., 111, 2626, 10.1073/pnas.1318306111 · DOI · Paper page
  9. Carmona-Gutierrez, 2016, The crucial impact of lysosomes in aging and longevity, Ageing Res. Rev., 32, 2, 10.1016/j.arr.2016.04.009 · DOI
  10. Cazes, 2007, Histologic cutaneous modifications after the use of EMLA cream, a diagnostic pitfall: review of 13 cases, Arch. Dermatol., 143, 1074, 10.1001/archderm.143.8.1074 · DOI
  11. Christensen, 2018, LRRK2 exonic variants associated with Parkinson's disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73, bioRxiv, 447946
  12. Cookson, 2016, Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease, Biochem. Soc. Trans., 44, 1603, 10.1042/BST20160228 · DOI
  13. Cuervo, 2000, When lysosomes get old, Exp. Gerontol., 35, 119, 10.1016/S0531-5565(00)00075-9 · DOI
  14. de Duve, 1974, Commentary. Lysosomotropic agents, Biochem. Pharmacol., 23, 2495, 10.1016/0006-2952(74)90174-9 · DOI · Paper page
  15. Deng, 2011, Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2, Nat. Chem. Biol., 7, 203, 10.1038/nchembio.538 · DOI
  16. Di Maio, 2018, LRRK2 activation in idiopathic Parkinson's disease, Sci. Transl. Med., 10, 10.1126/scitranslmed.aar5429 · DOI
  17. Dzamko, 2010, Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser910/Ser935, disruption of 14-3-3 binding and altered cytoplasmic localization, Biochem. J., 430, 405, 10.1042/BJ20100784 · DOI
  18. Dzamko, 2012, The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during toll-like receptor signaling, PLoS One, 7, 10.1371/journal.pone.0039132 · DOI
  19. Eguchi, 2018, LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis, Proc. Natl. Acad. Sci. U. S. A., 115, E9115, 10.1073/pnas.1812196115 · DOI
  20. Fan, 2018, Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils, Biochem. J., 475, 23, 10.1042/BCJ20170803 · DOI · Paper page
  21. Florey, 2015, V-ATPase and osmotic imbalances activate endolysosomal LC3 lipidation, Autophagy., 11, 88, 10.4161/15548627.2014.984277 · DOI
  22. Fraser, 2016, Ser(P)-1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease, Mov. Disord., 31, 1543, 10.1002/mds.26686 · DOI
  23. Fuji, 2015, Effect of selective LRRK2 kinase inhibition on nonhuman primate lung, Sci. Transl. Med., 7, 10.1126/scitranslmed.aaa3634 · DOI
  24. Fujimoto, 2018, Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology, Biochem. Biophys. Res. Commun., 495, 1708, 10.1016/j.bbrc.2017.12.024 · DOI
  25. Fujiwara, 2002, Alpha-Synuclein is phosphorylated in synucleinopathy lesions, Nat. Cell Biol., 4, 160, 10.1038/ncb748 · DOI
  26. Gardet, 2010, LRRK2 is involved in the IFN-gamma response and host response to pathogens, J. Immunol., 185, 5577, 10.4049/jimmunol.1000548 · DOI
  27. Goldman, 2010, Niemann-pick C1 functions independently of Niemann-pick C2 in the initial stage of retrograde transport of membrane-impermeable lysosomal cargo, J. Biol. Chem., 285, 4983, 10.1074/jbc.M109.037622 · DOI
  28. Gomez, 2019, Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases, J. Cell Biol., 218, 4157, 10.1083/jcb.201902184 · DOI · Paper page
  29. Gonzalez-Noriega, 1980, Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling, J. Cell Biol., 85, 839, 10.1083/jcb.85.3.839 · DOI
  30. Hakimi, 2011, Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures, J. Neural Transm. (Vienna), 118, 795, 10.1007/s00702-011-0653-2 · DOI
  31. Herzig, 2011, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice, Hum. Mol. Genet., 20, 4209, 10.1093/hmg/ddr348 · DOI
  32. Higashi, 2009, Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease, J. Neuropathol. Exp. Neurol., 68, 994, 10.1097/NEN.0b013e3181b44ed8 · DOI
  33. Hinkle, 2012, LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors, Mol. Neurodegener., 7, 25, 10.1186/1750-1326-7-25 · DOI
  34. Hoss, 1999, Histopathology of an adverse reaction to a eutectic mixture of the local anesthetics lidocaine and prilocaine, J. Cutan. Pathol., 26, 100, 10.1111/j.1600-0560.1999.tb01810.x · DOI
  35. Ito, 2014, Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955, PLoS One, 9, 10.1371/journal.pone.0097988 · DOI
  36. Kobayashi, 1999, Late endosomal membranes rich in lysobisphosphatidic acid regulate cholesterol transport, Nat. Cell Biol., 1, 113, 10.1038/10084 · DOI
  37. Kuwahara, 2020, The emerging functions of LRRK2 and Rab GTPases in the Endolysosomal system, Front. Neurosci., 14, 227, 10.3389/fnins.2020.00227 · DOI
  38. Kuwahara, 2016, LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts, Sci. Rep., 6, 29945, 10.1038/srep29945 · DOI · Paper page
  39. Kuzu, 2017, Effect of lysosomotropic molecules on cellular homeostasis, Pharmacol. Res., 117, 177, 10.1016/j.phrs.2016.12.021 · DOI
  40. Liu, 2018, LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network, Hum. Mol. Genet., 27, 385, 10.1093/hmg/ddx410 · DOI · Paper page
  41. MacLeod, 2013, RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk, Neuron., 77, 425, 10.1016/j.neuron.2012.11.033 · DOI · Paper page
  42. Madero-Perez, 2018, RAB7L1-mediated relocalization of LRRK2 to the golgi complex causes centrosomal deficits via RAB8A, Front. Mol. Neurosci., 11, 417, 10.3389/fnmol.2018.00417 · DOI · Paper page
  43. Marceau, 2012, Cation trapping by cellular acidic compartments: beyond the concept of lysosomotropic drugs, Toxicol. Appl. Pharmacol., 259, 1, 10.1016/j.taap.2011.12.004 · DOI
  44. Michalik, 2003, Procaine-induced enhancement of fluid-phase endocytosis and inhibition of exocytosis in human skin fibroblasts, Eur. J. Pharmacol., 475, 1, 10.1016/S0014-2999(03)02000-4 · DOI
  45. Mir, 2018, The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human, Biochem. J., 475, 1861, 10.1042/BCJ20180248 · DOI · Paper page
  46. Misinzo, 2008, Inhibition of endosome-lysosome system acidification enhances porcine circovirus 2 infection of porcine epithelial cells, J. Virol., 82, 1128, 10.1128/JVI.01229-07 · DOI
  47. Morissette, 2004, Massive cell vacuolization induced by organic amines such as procainamide, J. Pharmacol. Exp. Ther., 310, 395, 10.1124/jpet.104.066084 · DOI
  48. Paisan-Ruiz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron., 44, 595, 10.1016/j.neuron.2004.10.023 · DOI
  49. Pohlmann, 1984, Effect of monensin on intracellular transport and receptor-mediated endocytosis of lysosomal enzymes, Biochem. J., 217, 649, 10.1042/bj2170649 · DOI
  50. Purlyte, 2018, Rab29 activation of the Parkinson's disease-associated LRRK2 kinase, EMBO J., 37, 1, 10.15252/embj.201798099 · DOI · Paper page
  51. Reith, 2012, GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor, Bioorg. Med. Chem. Lett., 22, 5625, 10.1016/j.bmcl.2012.06.104 · DOI
  52. Sanyal, 2020, Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition, Mov. Disord., 35, 760, 10.1002/mds.27994 · DOI
  53. Satake, 2009, Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease, Nat. Genet., 41, 1303, 10.1038/ng.485 · DOI
  54. Sheng, 2012, Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations, Sci. Transl. Med., 4, 10.1126/scitranslmed.3004485 · DOI
  55. Steger, 2016, Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases, Elife., 5, 10.7554/eLife.12813 · DOI · Paper page
  56. Takano, 1984, Stimulation of the release of lysosomal and nonlysosomal granular enzymes from macrophages treated with monensin, Cell Struct. Funct., 9, 265, 10.1247/csf.9.265 · DOI
  57. Tapper, 1990, Role of lysosomal and cytosolic pH in the regulation of macrophage lysosomal enzyme secretion, Biochem. J., 272, 407, 10.1042/bj2720407 · DOI
  58. Thevenet, 2011, Regulation of LRRK2 expression points to a functional role in human monocyte maturation, PLoS One, 6, 10.1371/journal.pone.0021519 · DOI
  59. Tong, 2010, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice, Proc. Natl. Acad. Sci. U. S. A., 107, 9879, 10.1073/pnas.1004676107 · DOI
  60. Vallance, 2004, Pseudo-lysosomal storage disease caused by EMLA cream, J. Inherit. Metab. Dis., 27, 507, 10.1023/B:BOLI.0000037352.98317.5a · DOI
  61. Vilariño-Güell, 2011, VPS35 mutations in Parkinson disease, Am. J. Hum. Genet., 89, 162, 10.1016/j.ajhg.2011.06.001 · DOI · Paper page
  62. Villamil Giraldo, 2014, Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death, Biochem. Soc. Trans., 42, 1460, 10.1042/BST20140145 · DOI
  63. Weibrecht, 2010, Proximity ligation assays: a recent addition to the proteomics toolbox, Expert Rev. Proteomics., 7, 401, 10.1586/epr.10.10 · DOI
  64. Yahalom, 2019, Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: risk estimates and genotype-phenotype correlations, Parkinsonism Relat. Disord., 62, 179, 10.1016/j.parkreldis.2018.12.014 · DOI
  65. Ysselstein, 2019, LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients, Nat. Commun., 10, 5570, 10.1038/s41467-019-13413-w · DOI
  66. Zhang, 2009, Genomewide association study of leprosy, N. Engl. J. Med., 361, 2609, 10.1056/NEJMoa0903753 · DOI
  67. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron., 44, 601, 10.1016/j.neuron.2004.11.005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kuwahara, T., Funakawa, K., Komori, T., Sakurai, M., Yoshii, G., Eguchi, T., Fukuda, M., & Iwatsubo, T.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2020-11
Volume
145
Pages
105081
ISSN
0969-9961
DOI
10.1016/j.nbd.2020.105081
Cited by
80
References
2
Language
en
Licence
Funders
Japan Society for the Promotion of Science

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review